Recent clinical data have not supported certain immunomodulatory mechanisms of MSC therapy in IBD, which were reported in experimental models of chemically-induced colitis in rodents, such as the induction of FOXP3 + regulatory T lymphocytes (Treg)23. This evidence concerns the gene FOXP3 and colitis.